Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology at Sylvester Comprehensive Cancer Center, shared a post on X:
“Good news today for patients with EGFR exon 20 insertion-positive lung cancer that have not been able to access sunvozertinib – a drug that has been FDA approved since last July 2025 – now finally soon to be available via a global Liscence agreement with AstraZeneca.
But I won’t forget that while the the manufacturer was doing all these licensing negotiations my patients were progressing – How can we do better for patients and make drugs available faster?”
Other articles featuring Estela Rodriguez on OncoDaily.